("
Opening of 24/7 AI-Powered National Distribution Centre
Further to its announcement on
Included in the assets acquired by the Company's wholly owned subsidiary
Access to the pharmacy service will be advertised nationally and via the Company's MedPal app. At any time of day or night, users of the service will be able to complete an AI-supported consultation, which will produce a recommendation for a prescription, which will be signed off by a qualified Independent Prescriber ("IP") or General Practitioner ("GP") and then fulfilled at the Centre, which, being entirely automated, operates 24 hours a day. Medication will then be delivered to the user either the same or next day. There will be no charge to the user for the consultation or prescription, only for the medication.
Highlights
· Tripled footprint at
· Automation-led operations: installation of an Omnicell VBM and a BD Rowa VMAX advanced robotic dispensing system to increase throughput, accuracy and cost efficiency.
· AI-enabled triage:
· Faster access to treatment: launch of same-day and next-day delivery services for eligible prescription medicines, including weight-loss treatments and other therapies, subject to prescription and clinical suitability.
· 24/7 capability: continuous intake, verification and automated dispensing to improve service levels for both private and
Revolutionising Primary Care Through AI and Robotics
The Centre brings together MedPal's "digital front door" (including the MedPal app) and advanced robotic dispensing, delivering a vertically integrated, low-cost, high-reliability fulfilment model.
The expanded facility is designed to:
· increase access to primary-care pathways by providing rapid digital assessment and streamlined prescribing;
· lower unit costs through automation, enabling competitive pricing and improved patient affordability;
· enhance safety and quality via barcoded workflows, machine vision checks and pharmacist oversight; and
· support growth in both direct-to-consumer private prescriptions and
The Centre will initially focus on high-demand services including weight loss medications, and chronic disease management prescriptions with same-day delivery capability in key metropolitan areas and next-day delivery nationwide. The 24/7 operational model addresses the growing demand for telehealth services, particularly among working-age patients unable to access traditional GP surgeries during business hours.
At the heart of this development is the integration of MedPal's proprietary AI triage system with state-of-the-art robotic dispensing technology, which leverages AI and robotics to reduce dispensing errors, optimise inventory, and scale services to meet growing demand. This synergy allows MedPal app users to access telemedicine and telehealth services, optimising speed and affordability, making primary care available instantly and affordably, facilitating better health outcomes than conventional processes where users frequently encounter accessibility challenges such as delays and/or high costs.
"This distribution centre represents a milestone in our mission to democratise healthcare. By combining our
About
The addition of an AI-driven consumer platform with automated pharmacy operations to deliver timely, affordable access to medicines and telehealth pathways across the
View the link to watch an interview with CEO
https://editor.voxmarkets.co.uk/cms/article/68f7bedd066d459c83ca94bb
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic
Enquiries:
Jason Drummond, Chief Executive Officer
Cairn Financial Advisers LLP +44 20 7213 0880
Louise O'Driscoll/Jo Turner
Clear Capital Markets Limited +44 20 3869 6080
Bob Roberts/ Nick Josh
Square1 Consulting +44 20 7929 5599
David Bick +44 7831 381201
Forward Looking Statements
This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the